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Abstract
Background: Non-coding single nucleotide polymorphisms (SNPs) in GABRB2, the gene for b2-subunit of gamma-
aminobutyric acid type A (GABAA) receptor, have been associated with schizophrenia (SCZ) and quantitatively correlated to
mRNA expression and alternative splicing.
Methods and Findings: Expression of the Exon 10 region of GABRB2 from minigene constructs revealed this region to be an
‘‘alternative splicing hotspot’’ that readily gave rise to differently spliced isoforms depending on intron sequences. This led
to a search in human brain cDNA libraries, and the discovery of two novel isoforms, b2S1 and b2S2, bearing variations in the
neighborhood of Exon-10. Quantitative real-time PCR analysis of postmortem brain samples showed increased b2S1
expression and decreased b2S2 expression in both SCZ and bipolar disorder (BPD) compared to controls. Disease-control
differences were significantly correlated with SNP rs187269 in BPD males for both b2S1 and b2S2 expressions, and
significantly correlated with SNPs rs2546620 and rs187269 in SCZ males for b2S2 expression. Moreover, site-directed
mutagenesis indicated that Thr
365, a potential phosphorylation site in Exon-10, played a key role in determining the time
profile of the ATP-dependent electrophysiological current run-down.
Conclusion: This study therefore provided experimental evidence for the importance of non-coding sequences in the Exon-
10 region in GABRB2 with respect to b2-subunit splicing diversity and the etiologies of SCZ and BPD.
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Introduction
c-Aminobutyric acid (GABA) is the major inhibitory amino acid
neurotransmitter inthe vertebratenervoussystem.The fast synaptic
inhibition is mediated by the opening of a chloride channel formed
by the GABAA receptors. The GABAA receptors are also clinically
relevant drug targets for anti-convulsant, anxiolytic and sedative-
hypnotic agents. Subtypes of GABAA receptors are assembled from
pentameric combinations of a1-a6, b1-b3, c1-c3, r1-r3, e, d and p
subunits [1,2]. The molecular heterogeneity of GABAA receptor
subunits is further increased by the alternative splicing of some
subunit mRNAs, producing at least two isoforms of each of the a6,
b2, b3 and c2 subunits [3]. Most GABAA receptors are composed of
two a subunits, two b2 subunits and one c subunit [4]. The b2
subunit gene products of human GABRB2 expressed from cDNA
library are found in two alternatively spliced isoforms, the short
form b2S and the long form b2L. The inclusion of an extra 38-amino
acid Exon 10 in b2L but not in b2S in an intracellular loop brings
with it a potential phosphorylation site at Thr
365 for calmodulin-
dependent protein kinase II (Figure 1A)[5].
Schizophrenia (SCZ) and bipolar disorder (BPD) are major
psychotic disorders with a significant genetic component in their
complex etiology [6]. GABRB2, which encodes the b2 subunit of
GABAA receptors, contains single nucleotide polymorphisms
(SNPs) in non-coding sequences in the Intron 8-Intron 9 region
that have been associated with SCZ [7–10]. Moreover, the
expressions of b2S and b2L mRNA were found to be differentially
decreased in the dorsolateral prefrontal cortex (DLPFC) of SCZ
brains by real-time quantitative PCR, and these altered expres-
sions were correlated with the SCZ-associated SNPs rs1816071
and rs1816072 in SCZ subjects carrying the heterozygous
genotypes [11]. Since GABAA receptors containing b2L underwent
a steeper current run-down than those containing b2S under
conditions of ATP depletion induced by repeated GABA-
stimulation [11], these findings pointed to relationships between
the alternate splicing of the Exon 10 region with both GABA
current regulation and schizophrenia. It is therefore the objective
of the present study to examine the factors determining the
alternative splicing of Exon 10, and how the different b2 isoforms
might be correlated with the major psychotic disorders.
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Variability of Exon 10 splicing in vertebrates
Based on sequence alignments, Exon 10 is readily identified in
mammals and lizard, but not in chicken, frog (X. tropicalis) or fishes
(Figure 1A). In contrast, Exon 9 and Exon 11 are present in all of
these vertebrate species (Figure S1). Notably, expressions of Exon
10 have been reported for both humans [5] and chicken [12,13],
even though the Exon 10 sequence expressed in chicken bears little
resemblance to that in mammals. In the present study, expression
Figure 1. Characterizations of Exon 10 of GABRB2. (A) The exonic structure of human GABRB2 showing positions of the tagging SNPs, and the
alignment of its Exon 10 with corresponding sequences in other vertebrates (from UCSC Genome Browser). The lengths of the sequences
corresponding to the intervening sequences between E9 and E11 in the different species are indicated on the right. Dots represent identities; single
line, deletions; double-dashed line,unalignable bases. Exons are shown as numbered boxes. (B) RT-PCR analyses of Exon 10 expressions from rat,
mouse, human and monkey brain cDNA libraries with the common forward primer F2 against Exon 9 and reverse primer R4.2 against Exon 10 (Table
S4). (C) GABA-potentiated current rundowns of GABAA receptors containing a1, c2 and b2L-T365A.( D) The measured currents upon successive
additions of GABA expressed as % of the peak current elicited by the first addition of GABA. Significantly different responses between the a1
b2L-T365Ac2L (.) and a1b2Lc2L (%) receptors are marked by single (P,0.05) or double (P,0.01) asterisks. (E) Same as part D with 4 mM ATP infusion.
doi:10.1371/journal.pone.0006977.g001
Novel Isoforms of GABRB2
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e6977of Exon 10 was detected in rhesus monkey and mouse brains but
not in rat brain (Figure 1B). The full-length b2L coding sequences
amplified from monkey and mouse brain cDNA libraries also
confirmed the presence of b2L in these two species (Figure S2).
Thus there exist considerable variations among the vertebrates
with respect to Exon 10 expression.
The species variations in Exon 10 expression are paralleled by
variations in the length of the intervening gene segment between
Exon 9 and Exon 11(Figure 1A, right), which increases from
,3,000 bp in the fishes to 14,000–19,000 bp in non-mammalian
land vertebrates, and .28,000 bp in marsupial and placental
mammals. Furthermore, this region of the gene is readily blocked
by RepeatMasker, which identifies DNA sequences containing
interspersed repeats and low sequence complexity [14]. This
suggests that insertions and expansions of repeat elements could be
a significant contributing factor to the sharp increase in Exon 9-
Exon 11 length from the lower vertebrates to the higher
vertebrates. In fact, the sequence from 85-bp upstream to 66-bp
downstream of Exon 10 has been annotated as a candidate
LINE3, viz. a member of the Long Interspersed Nucleotide
Element family (UCSC GenomeBrowser: http://genome.ucsc.
edu/cgi-bin/hgTracks). Evolutionary changes in the lengths of the
gene segments corresponding to the other human introns in
GABRB2 are shown in Figure S3. Since only gene but not cDNA
sequences are available in various non-human species, their exact
exonic structures yet remain to be ascertained.
Expressions of human Exon 10 region from minigenes
In order to identify some of the effects of intronic sequences
flanking Exon 10 on the splicing of the region between Exon 9 and
Exon 11, minigene constructs containing Exons 2–9, a varying
length of Intron 9, Exon 10, an shortened Intron 10, and Exon 11
were constructed and expressed in Human embryonic kidney
(HEK) 293 cells (Figure 2). This wild-type (WT) minigene
construct containing a full length Intron 9, was unfavorable
toward the generation of Exon 10, as indicated by the absence of a
significant Exon 10-containing Band II DNA in the WT gel slot
(Lane 2, Figure 2A). Similarly, the D1, D3, D6, D7 and D8
minigenes, each containing a shortened Intron 9, also did not give
rise to any Band II DNA. Surprisingly, when the sequence
between bp 1,451 and 3,513 in Intron 9 was further deleted from
D1 to yield D2, a significant Exon 10-containing Band II was
obtained, along with a Band I which contained a novel Exon 10a
consisting of two segments of base sequences located between the
E9 and E10 sequences (Figure 2B and Figure S4). When D2
underwent a further shortening of Intron 9 in the direction toward
Exon 9 to yield D3, removing 451 bases including the rs187269
SNP site, both Exon 10 and Exon 10a disappeared. With still
further shortening of D3 to yield D4, a different novel Exon 10b
appeared in the form of Band IV. Shortening of D4 to yield D5 led
to a re-emergence of the Exon 10-containing Band II along with a
novel Exon 10c in the form of Band III. These observed exonal
variations encoded by minigenes WT and D1–D8 pointed to the
complexity of Exon 10 expression, in keeping with the relative ease
of generation of new splicing forms in this region.
Identification of potential isoforms from human brain
cDNA
The results described in Figure 2 revealed splicing variants that
generated three novel exons from the minigenes D2, D4 and D5:
Exon 10a from D2, Exon 10b from D4, and Exon 10c from D5. In
view of this observed propensity of the Exon 9-Exon 11 region to
give rise to these novel exons in minigene transfected cells, it
becomes of interest to determine whether the novel exons of this
kind might also be expressed in the human brain. Accordingly, a
human brain cDNA library (Resgen, Invitrogen) was PCR-
amplified with primers F1 (forward), and R1, R2, R3, R4 and
R5 (reverse) designed to amplify such novel exons, as illustrated in
Figure 2B and Figure 3A. The amplified PCR products shown in
Figure 3B were cloned into the pMD-18T vector and sequenced.
The sequencing results in Figure 3C showed that the Lane 1, Lane
2 and Lane 3 DNAs were all derived from a cDNA encoding a
novel isoform b2S1 that spanned from the F1 primer to a point
between the R3 and R4 primers. The absence of a visible DNA
band in Lane 4 indicated the lack of significant F1-R4 PCR
product. In Lane 5, a F1-R5 PCR reaction gave rise to three
distinct DNA sequences corresponding to the known long (b2L)
and short (b2S) isoforms together with a novel isoform b2S2.
The mRNA of the novel isoform b2S1, defined by the PCR
primers F1 and R3, was at least 2,470 bp in length. It contained a
39-extended Exon 9 from Intron 9 retention and was devoid of
Exons 3, 10 and 11, resulting in a 314-amino acid polypeptide. In
contrast, the mRNA of b2S2 was at least 1,362 bp in length, was
devoid of Exon 10, and contained an Exon 11 shortened by a 64-
bp deletion that brought about a frameshift-generated TAG to
result in a 373-amino acid polypeptide (Figure 3C). Figure 3D
shows the relative mRNA expression levels of b2S1 and b2S2 in
different human brain regions. Their relative amounts in the
cerebral cortex were: b2S.b2S2..b2S1.b2L.
Electrophysiological properties of recombinant receptors
The cell surface location of recombinant GABAA receptors
containing different isoforms of b2 together with a1 subunits upon
expression in HEK293 cells was indicated by immunofluorescence
staining (Figure 3E). The electrophysiological responses of these
receptors to GABA stimulation are shown in Figure S5A. The
half-maximal GABA effective concentration (EC50) of the a1b2-
myc receptors containing different isoforms of b2 ranged from 2.5–
3.4 mM (Table 1 and Figure S5B).
Previously it was found that upon repeated GABA-stimulations,
GABAA receptors containing b2L displayed a greater current run-
down compared to those containing b2S[11]. Since Thr
365,a
potential phosphorylation site for calmodulin dependent protein
kinase II, is present in b2L but not b2S, its possible involvement in
current run-down was examined by a Thr365Ala mutation to
yield the mutant construct b2L-T365A. When repeated receptor
activation was induced by exposure of cells transiently expressing
a1b2L-T365Ac2L, a1b2Lc2L or a1b2Sc2L to 300 mM GABA in the
absence of ATP infusion (Figure 1C), Figure 1D show that the
64.3% run-down reduction relative to initial current displayed by
the b2L-T365A-containing receptors was smaller than the 77.3%
reduction displayed by the wildtype b2L-containing receptors, and
practically the same as the 64.0% reduction displayed by the b2S-
containing receptors. These findings suggest that the greater
sensitivity of a1b2Lc2L relative to a1b2Sc2L toward current run-
down is caused by the depletion of intracellular ATP affecting the
phosphorylation status of Thr
365. In keeping with this, addition of
4 mM ATP to the intracellular infusate reduced the run-down
amplitudes of all three kinds of receptors, and effectively narrowed
the differences between them (Figure 1E and Figure S6).
Genetic correlations with isoform expressions in
psychotic disorders
Expressions of the four isoforms b2L, b2S, b2S1 and b2S2 in
DLPFC of postmortem CON, SCZ and BPD brains were
determined using quantitative real-time PCR, and normalized
by the geometric mean of the three reference genes glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), ubiquitin C (UBC)
Novel Isoforms of GABRB2
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The levels of b2S1 were significantly increased in both SCZ (by
43.0%, PLRS=0.038) and BPD (by 43.7%, PLRS=0.031)
(Figure 4A), whereas the levels of b2S2 were significantly decreased
in both SCZ (by 17.9%, PLRS=0.036) and BPD (by 22.6%,
PLRS=0.034). All these cases also passed the global significance test
with 1,000 permutations. These observations on b2S1 and b2S2
were compared to earlier results on b2S and b2L [11] in Figure 4A,
which showed that the mean expression levels of all four isoforms
in SCZ deviated significantly from the CON levels. The mean
expression levels in BPD deviated from the CON levels for b2S1
and b2S2, but not for b2S and b2L. When the sample characteristics
of gender, age, brain pH, postmortem interval (PMI), and sample
refrigeration interval (RFI) were included individually as a
covariate in UNPHASED analysis, the Wald test indicated no
significant covariate effect on b2S1 or b2S2 expression.
Previously the SNPs and haplotypes in the Intron 8-Intron 9
region (Figure S7) have been associated with SCZ [8,11]. The
results in Table S1 extended their associations to BPD.
Correlation analysis between the four isoform expressions and
different alleles, haplotypes and genotypes of the six tagging SNPs
in the combined CON-BPD-SCZ cohorts revealed significant
correlations for b2L or b2S at the allelic, genotypic as well as
haplotypic levels (Table 2). When the males were analyzed in
Figure 2. Effects of intronic sequences on Exon 10 expression in minigene constructs. (A) Minigenes of human GABRB2 and their
expressions in transfected cells. Left panel shows the structures of the minigenes; right panel shows the RT-PCR products amplified, using primers F2
and R0, from RNA derived from human brain or from minigene transfected-cells. Minigene WT consisted of E2-9, I9, E10, I10 (with a deletion ranging
from 1208 bp downstream of E10 to 1126 bp upstream of E11, as indicated by the gap), and E11. Minigenes D1–D8 each carried a further deletion
(shown as a gap) within I9. The determined sequences of Bands I–V are shown in Figure S4. (B) The proposed splicing origins of Bands I–V. Band II
contained [39portion of E9]-[E10]-[59portion of E11]; Band V contained [39portion of E9]-[59portion of E11]. Band I contained the 39-portion of E9, a
replacement of E10 by E10a, which was derived from a joining of the two grey boxes, plus the 59-portion of E11; Band III contained the 39-portion of
E9, a replacement of E10 by E10b derived from a joining of the two grey boxes, plus the 59-portion of E11; Band IV was similar to Band I, except that
one of the two grey boxes was different. The dotted bent lines between adjacent exons indicate fusion brought about by splicing, and the solid bent
lines indicate fusion brought about by deletion in the minigene construct.
doi:10.1371/journal.pone.0006977.g002
Novel Isoforms of GABRB2
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e6977Figure 3. Novel splicing isoforms of the human GABAA receptor b2 subunit. (A) Exonal structures of four different b2 subunit isoforms in human
brain. Line 1 shows GABRB2 structurewithexons indicatedby boxes (shadedfor codingregions,andunshadedfor non-codingregions).Lines2–5showthe
exonal compositions of alternatively spliced forms of b2.( B) EB-stained PCR products amplified from human brain cDNA library. Lane M, DNA standards;
Lanes 1–5,PCRproducts obtainedusingforwardprimerF1with reverseprimers R1-R5(TableS4),respectively.(C)AlignmentofthecDNAsequences ofthe
four isoforms. Base-pair numbering was based on b2LcDNA. Bases in uppercase representcoding sequences, andthosein lowercaserepresent non-coding
sequences. Exons E2-E12 are shown in alternating shaded/unshaded backgrounds. The dotted lines represent intervening sequences thatare not shownin
detail. Thedashed lines representgapped/absent sequences. The start-codonATG and stop-codons TAG or TAA are boxed. The italicized GAC spanning bp
1228–1294 incorporated a frame-shift that generated a 39 TAG termination codon for b2S2. The fourth transmembrane domain (TM4) is marked in part A
and underlined in part C.( D) The expression levels of b2S, b2S2, b2S1 and b2L in different human brain regions relative to b2S level in cerebral cortex were
determinedbymeansofreal-timePCR.Theamountsofdifferentisoformsinthecerebralcortex(greycolumns)relativetob2Swere: b2S2,0 . 47 ;b2S1,0.06;and
b2L 0.03. (E) Surface location of recombinant GABAA receptors containing different b2 subunits (scale bars=10 mm).
doi:10.1371/journal.pone.0006977.g003
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were also observed with b2S2 expression. The various effects
relating to isoform expressions involved particularly the tagging-
SNPs rs1816071, rs252944, rs187269, and rs34104385, all of
which were significantly associated with both BPD (Table S1) and
SCZ [8,11].
The relationships between isoform expressions and individual
genotypes of the six tagging SNPs were further analyzed in the
male samples using ANOVA both between and within diagnostic
groups (Figure 4B–4C and Table S2). The interdiagnostic group
comparisons with LSD tests showed that the MM genotypes of
rs1816071 (P=0.017) and rs187269 (P=0.009) significantly
increased b2S1 in BPD relative to CON (Figure 4B, indicated
by *). On the other hand, the Mm genotypes of rs1816071
(P=0.028), rs2546620 (P=0.010) and rs34104385 (P=0.047)
significantly reduced b2S2 in SCZ, and the Mm genotypes of
rs2546620 (P=0.037), rs187269 (P=0.004) and rs34104385
(P=0.047) significantly reduced b2S2 in BPD (Figure 4C, indicated
by *). When additionally tested by the Bonferroni post hoc test, the
significant correlations between MM of rs187269 and increased
b2S1 in BPD, between Mm of rs2546620 and decreased b2S2 in
SCZ, and between Mm of rs187269 and decreased b2S2 in BPD,
all remained significant at P,0.05 (as indicated by circled * in
Figure 4B–4C).
The intradiagnostic group comparisons showed that in the BPD
cohort, the Mm genotype of rs187269 significantly decreased b2S1
expression relative to the MM genotype (P=0.022) (Figure 4B,
indicated by #); the mm genotype of rs1816071 significantly
decreased b2S2 expression relative to MM (P=0.026) (Figure 4C,
indicated by #); and the Mm (P=0.004) and mm (P=0.033)
genotypes of rs187269 both significantly decreased b2S2 expression
relative to MM. In the SCZ cohort, the mm genotype of
rs1816071 significantly decreased b2S2 expression relative to MM
(P=0.029); the Mm genotype of rs2546620 significantly decreased
b2S2 expression relative to MM (P=0.044); and the mm genotypes
of rs187269 and rs34104385 both significantly decreased b2S2
expression relative to the MM as well as Mm genotypes (all
Ps,0.05) (Figure 4C, indicated by=). When additionally tested by
the Bonferroni post hoc test, some of these correlations remained
significant at P,0.05 (as indicated by circled # or = in Figure 4C).
Various P values are given in Table S2.
Discussion
Novel isoforms in a splicing hot-spot
The b2 subunit polypeptide of the GABAA receptors, encoded
by up to eleven exons, is known to exist in different isoforms: b2L
which contains Exon 10, and b2S which is devoid of Exon 10 [5].
Since the b2L and b2S expressions are associated with SCZ, and
also produce different effects on GABAA receptor run-downs, they
could provide a fundamental link between GABRB2 genotypes and
physiological perturbations in schizophrenia [11,15]. In the
minigene system, while minigene D2 gave rise to an Exon 10-
containing Band II and an Exon 10a-containing Band I, a
Figure 4. Correlations of isoform expressions with disease and
genotype. (A) Expressions of b2L, b2S, b2S1 and b2S2 in SCZ and BPD
relative to CON. The mean expressions of each of the four isoforms in
SCZ are represented by shaded columns, and the mean expressions in
BPD by clear columns. The CON level is represented by the horizontal
dashed line. Significant deviations (P,0.05) of mean expressions in SCZ
or BPD from CON, examined using UNPHASED, is marked by * above
columns. Relative expressions of b2S1 (part B) and b2S2 (part C) are
shown for the homozygous-major MM (grey), heterozygous Mm
(white), and homozygous-minor mm (hatched) genotypes of the
tagging SNPs rs1816071, rs2546620, rs187269, and rs34104385 in the
male CON, SCZ and BPD cohorts. Standard errors are indicated by bars.
Expression levels in BPD or SCZ that deviated significantly from CON
based on ANOVA with LSD post hoc test are marked by * above the
indicated comparison. Any expression level of Mm or mm that deviated
significantly from MM within the diagnostic group is marked by #. Any
expression level of mm that deviated significantly from both MM and
Mm is marked by=. After additional testing by the Bonferroni post hoc
test, those cases remaining significant (P,0.05) were marked as circled
*, # or =.
doi:10.1371/journal.pone.0006977.g004
Table 1. Electrophysiological parameters of splicing isoforms.
Isoform N EC50(mM) Hill coefficient Imax(nA)
a1b2S-myc 5 2.560.3 1.860.4 867683
a1b2S1-myc 8 2.660.1 2.060.2 696690
a1b2L-myc 6 3.160.3 1.860.2 877669
a1b2S2-myc 9 3.460.2 1.760.2 730643
N represents the cell number employed in each assay. The values shown are
mean 6 standard error.
doi:10.1371/journal.pone.0006977.t001
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expression-correlated and schizophrenia-associated SNP rs187269
[8] abolished both Band II and Band I. Likewise, other minigene
deletions gave rise to Exon 10b (expressed from D4) and Exon 10c
(expressed from D5). These findings pointed to the facile
occurrence of different splicing modes in the Exon 9-Exon 11
segment in response to intron sequence variations. They prompted
a search among human brain cDNAs for novel splicing products
and led to the discovery of the two novel b2 isoforms b2S1 and b2S2
in the brain. In the b2S1 isoform, Exon 9 is extended through
Intron 9 retention, and both Exons 3, 10 and 11 were omitted
(Figure 3A). In the b2S2 isoform, Exon 10 is omitted, and Exon 11
is shortened by a 64-bp deletion that brought about a frameshift-
generated TAG. The absence of Exon 11 from b2S1 and b2S2
implies the loss of the C-terminal transmembrane domain TM4
from these b2 isoforms. Functionally, the different b2 isoforms
displayed non-identical EC50 values. Since the EC50 values of b2S
(containing Exon 11) and b2S1 (devoid of Exon 11) were not
greatly different, Exon 11 and its constituent TM4 domain might
not be an important determinant of EC50. Similarly, since the
EC50 of b2L (containing Exon 10) was also not greatly different
from those of b2S, b2S1 and b2S2 (all devoid of Exon 10), Exon 10
also might not be an important determinant of EC50. That the
b2S2 isoform was not detected earlier was likely due to its similar
size as b2S, differing only by 64-bp, such that b2S2 was only found
through screening of individual clones bearing RT-PCR products.
The b2S1 isoform on the other hand has hitherto escaped detection
probably because it became detectible only using PCR primers
suggested by the minigene results.
The existence of as many as four isoforms, viz. b2S, b2S2, b2S1
and b2L arising from alternative splicings of the Exon 10 region
suggests that this region represents an ‘alternative-splicing hot-
spot’. The brain-region distributions of b2S, b2L and b2S2 were
largely similar whereas that of b2S1 was more dissimilar. Exons
10a, 10b and 10c, which were expressed only by minigenes (viz.
D2, D4 and D5 respectively) that carried a deletion in Intron 9,
were not detected in the brain.
Relationships between novel isoforms and psychotic
disorders
Based on the six tagging SNPs in the Intron 8-Intron 9 segment,
the results in Table 2 showed that the expression of the novel b2S2
isoform participated, at least among the males, along with the
expressions of b2S and b2L in a number of allelic, genotypic and
haplotypic correlations. As shown in Figure 4A, the expressions of
all four isoforms in SCZ deviated significantly from CON, and this
was also the case with b2S1 and b2S2 in BPD. Thus a derangement
in b2 isoform expressions represents an important characteristic
common to these two major psychotic disorders.
The genotypic effects recorded for the MM, Mm and mm
genotypes of rs187269 in Figure 4B showed generally higher levels
in the male BPD and SCZ cohorts compared to CON in
agreement with the overall increases in b2S1 in BPD and SCZ
(Figure 4A), with the positive correlations between b2S1 in BPD
and genotype reaching the P,0.05 significance level in the case of
rs187269 MM (Figure 4B). On the other hand, the genotypic
effects showed generally lower levels in the BPD and SCZ cohorts
compared to CON in agreement with the overall decreases in b2S2
in BPD and SCZ (Figure 4A), with the negative correlations
between b2S2 in SCZ and genotype reaching the P,0.05
significant level in the case of the rs2546620 Mm and negative
correlations between b2S2 in BPD and genotype also reaching the
P,0.05 significant level in the case of the rs187269 Mm
(Figure 4C). Thus the observed increases in b2S1 expression in
BPD in Figure 4A were led by increased expression by the MM
genotype more so than any increased expression by the Mm or
mm genotype, whereas the observed decreases in b2S2 expression
in BPD and SCZ were led by decreased expression by the Mm
genotype more so than any decreased expression by the MM or
mm genotype. Correspondingly, such genotype-dependent alter-
ations in b2S2 expression were supported by the statistically
significant inter-genotype differences (marked by # and = in
Figure 4C) observed in the BPD and SCZ cohorts, in contrast to
the absence of such differences in the CON cohort.
In conclusion, b2S1 and b2S2, the two novel isoforms of GABAA
receptor b2-subunit discovered in the present study, shared two
fundamental attributes with the previously known b2S and b2L
isoforms: the expressions of all four were significantly correlated
with not only SCZ or BPD or both, but also with the genotypes of
SNPs in the Intron 8-Intron 9 region of the GABRB2 gene. The
present study therefore has rendered even more unambiguous the
importance of the SNPs in this region of GABRB2 with respect to
isoform expressions and the etiologies of the two major psychotic
disorders.
Materials and Methods
DNA and RNA samples
RNA was extracted from tissue culture cells using guanidine
method [16]. Brain RNA samples from mouse, rhesus monkey,
and different human brain regions were purchased from BioChain
Institute. Postmortem brain DNA and RNA of 31 SCZ, 30 BPD
and 31 CON were donated by the Stanley Collection (Table S3)
[17]. After treatment with DNase I (Invitrogen), RNA was reverse
transcribed to cDNA. Reaction was carried out with 2 mg of total
RNA, random hexamers and TaqMan Reverse Transcription Kit
(Applied Biosystems) for 10 min at 25uC, 30 min at 48uC, 5 min
at 95uC.
Oligonucleotide primers and probes
The primers for PCR, DNA sequencing and cloning, and
probes of GABRB2 isoforms and GAPDH for real-time PCR were
designed using Primer Express 3.0 (Applied Biosystems Inc., Foster
City, CA), as described in Table S4, and obtained from Proligo
Singapore Pte Ltd. TaqMan Expression Assays (Applied Biosys-
tems) were employed for UBC and HMBS.
Minigene construction
A fragment that spanned from the start of Exon 9 to 1207 bp
downstream of Exon 10 of GABRB2 was amplified from human
genomic DNA with the addition of a GCTCTAGA sequence
(where the underlined sequence represents an XbaI site) to its 39
end. This amplified fragment was cloned into the pMD18-T
vector to yield pMD18T-I. Another fragment spanning from
1127 bp upstream of Exon 11 to the end of Exon 11 of GABRB2
was likewise amplified from human genomic DNA with the
additions of a GCTCTAGA (where the underlined sequence
represents an XbaI site) to both its 59 and 39 terminals. This
amplified fragment was cloned into the pMD18T-I via the XbaI
site to yield pMD18T-I/II, such that the cloned insert contained
sequentially Exon 9, Intron 9, Exon 10, a shortened Intron 10, and
Exon 11. The insert in pMD18T-I/II was in turn digested out
with ApaI (located in Exon 9) and Xho I (in Exon 11), and inserted
into the corresponding sites in Exon 9 and Exon 11 of the
pcDNA3.1-b2S construct, which carries the coding region of b2
cDNA without any intron. The resultant human GABAA receptor
b2 minigene was designated as WT: it contained sequentially part
of Exon 2, Exons 3–9 (coding region only and devoid of Introns
Novel Isoforms of GABRB2
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deletion (bp 160,655,142–160,684,744 inclusive on Chromosome 5)
and Exon 11 (Figure2A). A series of deletions of WTwere performed
using the QuikChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA) to yield D1 (with a deletion of bases 3513 to 3630 inclusive
of Intron 9), D2 (with a deletion of bases 1451 to 3630 inclusive of
Intron 9),D3 (with a deletion of bases 1000 to 3630 inclusive of Intron
9), D4 (with a deletion of bases 518 to 3630 inclusive of Intron 9), D5
(with a deletion of bases 72 to 3630 inclusive of Intron 9), D6( w i t ha
deletion of bases 72 to 2818 inclusive of Intron 9), D7 (with a deletion
of bases 72 to 1880 inclusive of Intron 9), and D8 (with a deletion of
bases 72 to 981 inclusive of Intron 9). WT and its various deletions
were transfected into HEK293 cells, and expression of GABRB2
mRNA in the cells was monitored using RT-PCR using the primers
located in Exon 9 and Exon 11.
Expression constructs
The coding regions of the human GABAA receptor a1, b2S, b2L
and c2L subunit cDNAs were amplified from human brain cDNA
libraries (Resgen, Invitrogen), and individually cloned into the
mammalian expression vector pcDNA3.1 (Stategene, USA) as
described previously [11]. The site-directed mutant pcDNA3.1-
b2L-T365A was generated with the PCR-based Mutagenesis Kit
from Stratagene. To facilitate protein detection, the Myc tag was
fused into the C-terminal of the b2L, b2S, b2S1 and b2S2 subunits by
cloning into pCI-neo-Myc expression vector (Promega). Briefly,
the flanking restriction sites EcoR I and Xha I were added on
respectively to the 59 terminal and 39 terminal of the b2L, b2S, b2S1
and b2S2 cDNAs by PCR amplification. After digestion with EcoR
I and Xba I, the cDNAs were inserted into the corresponding sites
in pCI-neo-Myc vector. The fidelity of the final expression
constructs were verified by DNA sequencing.
Cell cultures and transfections
HEK293 cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented by 10% fetal bovine serum (Invitrogen),
and transfected using Lipofectamine & Plus reagents (Invitrogen)
following the manufacturer’s instructions. Transfection was
performed either in 35 mm dishes with 3 mg/dish plasmid DNA,
or in 12-well plates with 1.2 mg/well plasmid DNA. Cells were
employed for RNA extraction, immunostaining and electrophys-
iology 48 h after transfection.
Properties of recombinant GABAA receptors
For immunostaining, cells plated on poly-L-lysine coated
coverslips were fixed in paraformaldehyde. After blocking with
bovine serum albumin and anti-Myc antibody (9E10 from mouse,
diluted 1:500), fluorescein-conjugated goat anti-mouse IgG (from
goat and ditulted 1:100; Molecular Probe) was applied, and
immunostaining was examined using a Nikon TE2000E fluores-
cence microscope.
The recording of GABA dose-current responses in HEK293
cells containing recombinant receptors by means of whole-cell
patch-clamping, and the induction of receptor run-down by
repeated GABA-stimulations, was performed as described [11,18].
Variation of current with GABA concentration was fitted to the
Hill equation to estimate EC50 and Hill coefficient (nH).
Quantitative PCR and DNA sequencing
Quantitative real-time PCR was performed with TaqMan
Probe as described [11] (Table S4). The geometric mean of three
reference genes GAPDH, HMBS and UBC was employed for
normalization of GABRB2 expression [19].
Genotypes of various SNP and of a 12-bp sequence at
rs34104385 were determined by sequencing of a PCR-amplified
4,469 bp segment spanning from 2,185 bp upstream to 2,039 bp
downstream of Exon 9 of GABRB2 (Figure S7), as described [11].
Statistical analysis
Sequence alignments of GABRB2 gene among different species
were downloaded from UCSC Genome Browser website. Analyses
of disease association of SNPs and two-SNP haplotypes, and
analyses of correlations between isoform expression and disease
status, allele, genotype or haplotype, were carried out with the
likelihood ratio statistic (LRS) test to generate the PLRS value using
UNPHASED program version 3.0.7 [11,20]. Covariate analyses
of demographic or clinical characteristics were performed using
the Wald-test in UNPHASED v3.07; each case showing
PLRS,0.05 was further evaluated by the LRS test with 1,000
permutations to generate a global PGlob value. Correlations
between isoform expression and genotype were analyzed using
ANOVA with LSD and Bonferroni post hoc tests in SPSS v11.5.
Supporting Information
Figure S1 Sequence alignments of (A) Exon 9 and (B) Exon 11
from different vertebrate species were downloaded from UCSC
genome browser (http://genome.ucsc.edu/cgi-bin/hgGateway).
Found at: doi:10.1371/journal.pone.0006977.s001 (0.51 MB JPG)
Figure S2 The full-length b2L coding sequences from mouse (A)
and monkey (B) brain cDNA libraries. RT-PCRs were performed
with the three forward primers and three reverse primers given in
Table S4, and the products were cloned into T-vector. The
positive clones were validated by DNA sequencing.
Found at: doi:10.1371/journal.pone.0006977.s002 (0.70 MB JPG)
Figure S3 Intron sizes of GABRB2 in vertebrate species.
Found at: doi:10.1371/journal.pone.0006977.s003 (0.20 MB JPG)
Figure S4 The cDNA sequences of Bands I, II, III, IV and V
shown in Figure 2 determined by cloning the cDNA in pMD-18T
vector and sequencing. Band I cDNA was obtained from D2, Band
II from human brain, D2 and D5, Band III from D5, Band IV
from D4, and Band V from all of human brain, WT and D1-D8.
The dashed arrows represent the PCR primer binding regions
used in RT-PCR. The boxed sequences indicate the exon (Exon
10, Exon 10a, Exon 10b or Exon 10c) found in each instance
between Exon 9 and Exon 11. There was no such exon in the case
of Band V. The slash within the novel exons in I, III, IV indicates
in each instance the gapped position in the minigene construct.
Found at: doi:10.1371/journal.pone.0006977.s004 (0.46 MB JPG)
Figure S5 GABA concentration-response currents (A) and
curves (B) from transfected HEK293 cells expressing different
isoforms of b2 together with a1 subunits. Recordings of
representative current response of different doses of GABA are
illustrated in part A. In part B, from left to right at 50% Imax
(marked by horizontal dotted line): a1b2S-Myc, a1b2S1-Myc,
a1b2L-Myc and a1b2S2-Myc, each representing the average
estimate obtained with 5-9 cells through data fitted to the Hill
equation.
Found at: doi:10.1371/journal.pone.0006977.s005 (0.30 MB
DOC)
Figure S6 GABA-potentiated current rundowns of GABAA
receptors. Repeated GABAA receptors activation was reduced by
exposure of cells transiently expressing a1, c2 plus one of the
b2L-T365A, b2L,o rb2S to 300 mM of GABA in the presence of
4 mM of ATP infusion
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Figure S7 The positions of SNPs in the Intron 8-Intron 9 of
GABRB2 examined in the present study. SNP rs34104385 is a
polymorphic site consisting of a 12-bp insertion-deletion variation
(indel) followed by a A/C SNP, where the major A-allele is linked
to the deletion form, and the minor C-allele is linked to the
insertion form.
Found at: doi:10.1371/journal.pone.0006977.s007 (0.18 MB JPG)
Table S1 PLRS-values relating to association of single SNPs and
two-SNP haplotypes of GABRB2 with male BPD and SCZ cohort.
The SCZ vs CON results, with the exception of those relating to
rs34104385, were based on Ref. 11. The PLRS-values shown were
obtained with UNPHASED 3.07. Only those PLRS,0.05 further
confirmed to be significant after 1,000 permutations are shown in
bold font.
Found at: doi:10.1371/journal.pone.0006977.s008 (0.01 MB
DOC)
Table S2 Genotypic correlations with expressions of b2S1 and
b2S2 in the male SCZ, BPD and CON cohorts. Genotypic effects
of the tagging SNPs rs1816071, rs2546620, rs187269 and
rs34104385 on b2S1 and b2S2 expressions are shown for the male
SCZ, BPD and CON cohorts. N represents the number of samples
of each of the three genotypes MM, Mm and mm. Overall
genotypic effects on b2S1 and b2S2 expressions were assessed using
ANOVA. Pair-wise genotype comparisons (MM vs. Mm, Mm vs.
mm and MM vs. mm) were evaluated with LSD post hoc test in
ANOVA, and the results were shown as PL; the instances with
PL,0.05 were further evaluated with Bonferroni post hoc test in
ANOVA, and the results were shown as PB. In all instances,
P,0.05 values are shown in bold font. The three Mean Ratios for
each group refer to the expression level of, from top to bottom, the
ratio of MM over Mm, Mm over mm, and MM over mm.
Found at: doi:10.1371/journal.pone.0006977.s009 (0.09 MB
DOC)
Table S3 Demographic and clinical information on subjects
used in this study. Mean 6 standard deviation; M, male; F,
female; PMI, postmortem interval; BW, brain weight; RFI,
duration of refrigerator storage; AOO, age of onset; TIH, time
in hospital; DOI, duration of illness; LFPZ, lifetime of antipsy-
chotic exposure in terms of fluphenazine equivalent in grams.
a35
CON, 35 SCZ and 35 BPD were provided by Stanley Research
Foundation and 13 from three groups giving no RT-PCR
products were excluded from this study.
bRNA sample obtained
from BioChain Institute included one from rhesus monkey cortex,
and 17 different human brain regions, with age of individual in
parenthese: cerebral cortex (23), cerebellum (29), cerebral
meninges (21), corpus callosum (27), diencephalon (29), postcentral
gyrus (41), precentral gyrus (26), hippocampus (82), frontal lobe
(41), occipital lobe (27), parietal lobe (26), temporal lobe (26),
medulla oblongata (60), olfactory (87), pons (36), pituitary (53) and
thalamus (71).
Found at: doi:10.1371/journal.pone.0006977.s010 (0.01 MB
DOC)
Table S4 Primers and probes used in this study. Restriction sites
are underlined.
Found at: doi:10.1371/journal.pone.0006977.s011 (0.02 MB
DOC)
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